Eli Lilly has announced positive Phase 3 results showing that its BTK inhibitor Jaypirca (pirtobrutinib) significantly improved outcomes for patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when combined with a fixed-duration venetoclax-based regimen. The findings add to growing evidence that targeted combination therapies may help patients achieve longer periods of disease control without continuous treatment.

Lundbeck has unveiled promising early-stage clinical data for its investigational therapy asedebart, highlighting a potential new treatment approach for patients living with Cushing’s disease, a rare endocrine disorder driven by excessive cortisol production. The findings were presented at the ENDO 2026 Annual Meeting in Chicago.

Johnson & Johnson has reported encouraging Phase 3 results for a combination therapy featuring TALVEY (talquetamab-tgvs) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), highlighting the growing potential of bispecific antibody-based treatment strategies in earlier-line relapsed or refractory multiple myeloma (RRMM).